Many cancers evade immune surveillance by suppressing immune activation and creating an immunosuppressive tumor microenvironment. OncoTarget is designed to overcome these barriers by activating both innate and adaptive immune responses against cancer cells.

Therapeutic Rationale

The combination of NK cells and DC-T cell therapies offers a synergistic approach to cancer treatment by enabling direct tumor cell killing while simultaneously generating durable, antigen-specific immune memory.

• • NK cell–mediated direct cytotoxicity against tumor cells
• • Dendritic cell–driven antigen presentation and T-cell activation
• • Enhancement of tumor-specific immune recognition
• • Modulation of the tumor microenvironment to support immune infiltration

Potential Benefits

OncoTarget is being developed to provide meaningful therapeutic benefits across multiple cancer types, including:

• • Improved tumor targeting and immune-mediated tumor control
• • Reduced risk of tumor immune escape
• • Potential for long-lasting anti-tumor immune responses
• • Complementary use alongside existing cancer therapies

Development Focus

OncoTarget is part of RCT’s immuno-oncology research pipeline. Current development efforts focus on immune cell optimization, safety profiling, and translational readiness to support future clinical evaluation in oncology indications.